PL2349220T3 - Zastosowanie rozpuszczalników organicznych w granulacji na mokro moksyfloksacyny - Google Patents

Zastosowanie rozpuszczalników organicznych w granulacji na mokro moksyfloksacyny

Info

Publication number
PL2349220T3
PL2349220T3 PL08807939T PL08807939T PL2349220T3 PL 2349220 T3 PL2349220 T3 PL 2349220T3 PL 08807939 T PL08807939 T PL 08807939T PL 08807939 T PL08807939 T PL 08807939T PL 2349220 T3 PL2349220 T3 PL 2349220T3
Authority
PL
Poland
Prior art keywords
moxifloxacin
organic solvents
wet granulation
granulation
wet
Prior art date
Application number
PL08807939T
Other languages
English (en)
Inventor
Farhad Farshi
Recep Avci
Fikret Koc
Serdar Soylemez
Original Assignee
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40070762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2349220(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of PL2349220T3 publication Critical patent/PL2349220T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL08807939T 2008-10-09 2008-10-09 Zastosowanie rozpuszczalników organicznych w granulacji na mokro moksyfloksacyny PL2349220T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2008/054141 WO2010041100A1 (en) 2008-10-09 2008-10-09 Using of organic solvents in wet granulation of moxifloxacin
EP08807939A EP2349220B1 (en) 2008-10-09 2008-10-09 Using of organic solvents in wet granulation of moxifloxacin

Publications (1)

Publication Number Publication Date
PL2349220T3 true PL2349220T3 (pl) 2012-12-31

Family

ID=40070762

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08807939T PL2349220T3 (pl) 2008-10-09 2008-10-09 Zastosowanie rozpuszczalników organicznych w granulacji na mokro moksyfloksacyny

Country Status (12)

Country Link
US (1) US8314122B2 (pl)
EP (1) EP2349220B1 (pl)
JP (1) JP5461565B2 (pl)
CN (1) CN102176902B (pl)
BR (1) BRPI0823092A2 (pl)
EA (1) EA201170545A1 (pl)
ES (1) ES2391132T3 (pl)
MX (1) MX2011003731A (pl)
PL (1) PL2349220T3 (pl)
PT (1) PT2349220E (pl)
TR (1) TR201106844T2 (pl)
WO (1) WO2010041100A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200907227A2 (tr) * 2009-09-18 2011-04-21 Bi̇lgi̇ç Mahmut Çözünürlüğü yüksek stabil mikronize granüller.
EP2491921A1 (en) * 2011-02-25 2012-08-29 Deva Holding Anonim Sirketi Conservation of anhydrous form of gemifloxacin
CN102204911B (zh) * 2011-03-25 2013-04-17 华润赛科药业有限责任公司 一种盐酸莫西沙星药物组合物及其制备方法
BRPI1106900A2 (pt) * 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
FR2992218B1 (fr) 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
SI3265084T1 (sl) * 2015-03-03 2024-04-30 Pharmacyclics Llc Farmacevtske formulacije inhibitorja Burtonove tirozin kinaze

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
EP0782449B1 (en) * 1994-09-22 2003-04-09 Akzo Nobel N.V. Process of making dosage units by wet granulation
DE19546249A1 (de) * 1995-12-12 1997-06-19 Bayer Ag Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
DK1128831T3 (da) * 1998-11-10 2005-01-17 Bayer Healthcare Ag Farmaceutisk moxifloxacinpræparat
EP1562942A1 (en) * 2002-10-31 2005-08-17 Ranbaxy Laboratories, Ltd. Amorphous moxifloxacin hydrochloride
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds
US7230006B2 (en) * 2003-04-09 2007-06-12 Reddy's Laboratories Limited Crystalline form III of anhydrous moxifloxacin hydrochloride and a process for preparation thereof
US20050031683A1 (en) * 2003-08-04 2005-02-10 Ashish Kapoor Solid pharmaceutical composition
DE102005036195A1 (de) 2005-08-02 2007-02-08 Robert Bosch Gmbh Handwerkzeugmaschine
GB0612422D0 (en) * 2006-06-23 2006-08-02 Generics Uk Ltd Novel hydrate form

Also Published As

Publication number Publication date
CN102176902B (zh) 2012-10-31
US20110198774A1 (en) 2011-08-18
EA201170545A1 (ru) 2012-01-30
ES2391132T3 (es) 2012-11-21
BRPI0823092A2 (pt) 2015-09-29
EP2349220A1 (en) 2011-08-03
PT2349220E (pt) 2012-10-11
JP2012505194A (ja) 2012-03-01
EP2349220B1 (en) 2012-07-25
JP5461565B2 (ja) 2014-04-02
WO2010041100A1 (en) 2010-04-15
US8314122B2 (en) 2012-11-20
MX2011003731A (es) 2011-08-03
CN102176902A (zh) 2011-09-07
TR201106844T2 (tr) 2012-02-21

Similar Documents

Publication Publication Date Title
HRP20190016T1 (hr) Heterociklički spojevi i njihova upotreba
IL246600B (en) Heterocyclic compounds and their use
EP2274435A4 (en) RECOVERING ORGANIC ACIDS
ZA201006505B (en) Novel heterocyclic compounds and uses thereof
EP2427195A4 (en) HETEROCYCLIC COMPOUNDS AND USES THEREOF
BRPI0912026A2 (pt) formulação homeopática
EP2637669A4 (en) Heterocyclic compounds and their use
ZA201104104B (en) Improved solvent removal
EP2575462A4 (en) Heterocyclic compounds and their use
ZA201101123B (en) Nicotine-containing granulate
EP2376408A4 (en) FLUORATION OF ORGANIC COMPOUNDS
IL208601A0 (en) Dried formulations
EP3572073C0 (en) FREEZE DRYING ABOVE COLLAPSING TEMPERATURE
HRP20150932T1 (en) Heterocyclic compounds
EP2262426A4 (en) VEHICULAR SOLVENT FOR DYKLOSCOPIC FORMULATIONS
PL2349220T3 (pl) Zastosowanie rozpuszczalników organicznych w granulacji na mokro moksyfloksacyny
GB0811455D0 (en) Improvements in & relating to solvent processing
GB0822323D0 (en) Drying aid composition
HK1156209A1 (en) Stable benzimidazole formulation
GB0821360D0 (en) Solvent
GB0822020D0 (en) Uses of clenbuterol
GB0802827D0 (en) Purely bodies
EP2312948A4 (en) 5-CHINOLINONE AND IMIDAZOPYRIDINE COMPOUNDS AND THEIR USE
IL208925A0 (en) Stable benzimidazole formulation